CoChat

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m 2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected.

Overview

Integrity signals

Registry

Crossref · 10.1159/000356018

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Cited by

See all 8

Metadata

Authors
Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Hasegawa, J., Hata, T., Takemasa, I., Ikeda, M., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., Mori, M., & on behalf of the Clinical Study Group of Osaka University (CSGO), C. G.
Affiliations
  • The University of Osaka (JP)
  • Suita Municipal Hospital (JP)
  • Hannan University (JP)
  • Sakai City Medical Center (JP)
  • Osaka Prefectural Medical Center (JP)
  • Osaka Rosai Hospital (JP)
  • Toyonaka Municipal Hospital (JP)
  • Osaka National Hospital (JP)
  • Nishinomiya Municipal Central Hospital (JP)
Venue
Oncology
Publisher
S. Karger AG
Published
2013
Volume
85
Issue
6
Pages
317-322
ISSN
  • 0030-2414 (ISSN-L)
  • 1423-0232
OpenAlex
W2019831318
Cited by
8
References
18
Citations by year
2024: 1 · 2020: 1 · 2017: 1 · 2015: 2 · 2014: 3
FWCI
0.89
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords
metastatic colorectal cancer, S-1, irinotecan, bevacizumab, first-line chemotherapy, combination chemotherapy, response rate, progression-free survival, overall survival, neutropenia, diarrhea
MeSH terms
Bevacizumab, Irinotecan, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Colonic Neoplasms, Drug Combinations, Female, Tegafur, Humans, Male, Middle Aged, Neoplasm Metastasis, Oxonic Acid, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.